{"parse":{"title":"C-terminal telopeptide","pageid":31170355,"revid":768652572,"text":{"*":"<div class=\"mw-parser-output\"><p>In <a href=\"/wiki/Physiology\" title=\"Physiology\">bone physiology</a>, <b>the C-terminal telopeptide</b> (or more formally, <b>carboxy-terminal collagen crosslinks</b>, and known by the <a href=\"/wiki/Acronym\" title=\"Acronym\">acronym</a> <b>CTX</b>) is a <a href=\"https://en.wiktionary.org/wiki/telopeptide\" class=\"extiw\" title=\"wikt:telopeptide\">telopeptide</a> that can be used as a <a href=\"/wiki/Biomarker_(medicine)\" title=\"Biomarker (medicine)\">biomarker</a> in the <a href=\"/wiki/Serum_(blood)\" title=\"Serum (blood)\">serum</a> to measure the rate of <a href=\"/wiki/Bone_remodeling\" title=\"Bone remodeling\">bone turnover</a>. It can be useful in assisting clinicians to determine a patient's nonsurgical treatment response as well as evaluate a patient's risk of developing complications during healing following surgical intervention.<sup id=\"cite_ref-MarxCTX_1-0\" class=\"reference\"><a href=\"#cite_note-MarxCTX-1\">&#91;1&#93;</a></sup>  The test used to detect the CTX marker is called the Serum CrossLaps, and it is more specific to <a href=\"/wiki/Bone_resorption\" title=\"Bone resorption\">bone resorption</a> than any other test currently available.<sup id=\"cite_ref-ROSEN_2-0\" class=\"reference\"><a href=\"#cite_note-ROSEN-2\">&#91;2&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Bisphosphonate-associated_osteonecrosis_of_the_jaw\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Bisphosphonate-associated osteonecrosis of the jaw</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Risk_determination\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Risk determination</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Use_of_the_CTX_biomarker\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Use of the CTX biomarker</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#See_also\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#References\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Bisphosphonate-associated_osteonecrosis_of_the_jaw\">Bisphosphonate-associated osteonecrosis of the jaw</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=C-terminal_telopeptide&amp;action=edit&amp;section=1\" title=\"Edit section: Bisphosphonate-associated osteonecrosis of the jaw\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Bisphosphonate-associated_osteonecrosis_of_the_jaw\" class=\"mw-redirect\" title=\"Bisphosphonate-associated osteonecrosis of the jaw\">Bisphosphonate-associated osteonecrosis of the jaw</a></div>\n<p>In the early 2000s, a link between <a href=\"/wiki/Bisphosphonate\" title=\"Bisphosphonate\">bisphosphonate</a> use and impaired bone physiology was noted.<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup>  The strong inhibition of <a href=\"/wiki/Osteoclast\" title=\"Osteoclast\">osteoclast</a> function precipitated by bisphosphonate therapy can lead to inhibition of normal bone turnover, leading to impaired wound healing following trauma (such as dental surgery) or even spontaneous non-healing bone exposure.  Because bisphosphonates are preferentially deposited in bone with high turnover rates, it is possible that the levels of bisphosphonate within the jaw bones are selectively elevated.<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Risk_determination\">Risk determination</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=C-terminal_telopeptide&amp;action=edit&amp;section=2\" title=\"Edit section: Risk determination\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>With the advent of implant dentistry, more dental patients are undergoing therapies in the oral cavity that involve bone healing, such as surgical implant placement and bone grafting procedures.  In order to evaluate the risk of osteonecrosis for a patient taking bisphosphonates, use of the CTX biomarker was introduced in 2000 by Rosen.<sup id=\"cite_ref-ROSEN_2-1\" class=\"reference\"><a href=\"#cite_note-ROSEN-2\">&#91;2&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Use_of_the_CTX_biomarker\">Use of the CTX biomarker</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=C-terminal_telopeptide&amp;action=edit&amp;section=3\" title=\"Edit section: Use of the CTX biomarker\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Although a number of <a href=\"/wiki/Surrogate_endpoint\" title=\"Surrogate endpoint\">surrogate biomarkers</a> exist for measuring the metabolic products of bone resorption, the serum CTX marker was chosen because it is both highly correlated to bone turnover rate and already available for detection in a laboratory test carried out by a major lab testing corporation.<sup id=\"cite_ref-MarxCTX_1-1\" class=\"reference\"><a href=\"#cite_note-MarxCTX-1\">&#91;1&#93;</a></sup>\n</p><p>The CTX test measures for the presence and concentration of a crosslink <a href=\"/wiki/Peptide\" title=\"Peptide\">peptide</a> sequence of <a href=\"/wiki/Type-I_collagen\" class=\"mw-redirect\" title=\"Type-I collagen\">type I collagen</a>, found, among other tissues, in bone.  This specific peptide sequence relates to bone turnover because it is the portion that is cleaved by <a href=\"/wiki/Osteoclast\" title=\"Osteoclast\">osteoclasts</a> during bone resorption, and its serum levels are therefore proportional to osteoclastic activity at the time the blood sample is drawn.<sup id=\"cite_ref-MarxCTX_1-2\" class=\"reference\"><a href=\"#cite_note-MarxCTX-1\">&#91;1&#93;</a></sup>  Serum levels in healthy patients not taking bisphosphonates tends to hover above 300 <a href=\"/wiki/Kilogram#SI_multiples\" title=\"Kilogram\">pg</a>/mL.\n</p>\n<style data-mw-deduplicate=\"TemplateStyles:r856303468\">.mw-parser-output .templatequote{overflow:hidden;margin:1em 0;padding:0 40px}.mw-parser-output .templatequote .templatequotecite{line-height:1.5em;text-align:left;padding-left:1.6em;margin-top:0}</style><blockquote class=\"templatequote\"><p>\"Even though laboratory normal ranges are said to be between 50 pg/mL and 450 pg/mL, this normal range is not accurate related to the <a href=\"/wiki/Osteoporosis\" title=\"Osteoporosis\">osteoporosis</a> population. Actual normal values are usually well over 300 pg/mL and are most commonly 400 pg/mL to 550 pg/mL in patients not taking bisphosphonates. Lower values represent varying degrees of suppression of normal bone turnover, sometimes also called <a href=\"/wiki/Bone_remodeling\" title=\"Bone remodeling\">bone remodeling</a> or bone renewal.\"<sup id=\"cite_ref-MarxCTX_1-3\" class=\"reference\"><a href=\"#cite_note-MarxCTX-1\">&#91;1&#93;</a></sup>\n</p></blockquote>\n<p>Patients who are placed on a 6-month <a href=\"/wiki/Drug_holiday\" title=\"Drug holiday\">drug holiday</a> exhibit marked improvements in their serum CTX values; in one study, patients showed an improvement of 155.3 pg/mL over 6 months or a rate of 25.9 pg/mL each month.<sup id=\"cite_ref-MarxCTX_1-4\" class=\"reference\"><a href=\"#cite_note-MarxCTX-1\">&#91;1&#93;</a></sup>\n</p><p>Initially, urinary CTX levels were sought, but this proved to offer no greater value than urinary <a href=\"/wiki/N-terminal_telopeptide\" title=\"N-terminal telopeptide\">NTX</a> values\u2014both tests suffered from large spontaneous fluctuations unrelated to therapy or intervention, and were therefore largely unreliable.<sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup>  In contrast, the <a href=\"/wiki/Monoclonal_antibody\" title=\"Monoclonal antibody\">monoclonal antibody</a> test for detecting serum CTX levels features minimal spontaneous disruption yet remarkable change to antiresorptive therapy, making the serum CTX assay both highly <a href=\"/wiki/Sensitivity_and_specificity\" title=\"Sensitivity and specificity\">sensitive and specific</a>.<sup id=\"cite_ref-ROSEN_2-2\" class=\"reference\"><a href=\"#cite_note-ROSEN-2\">&#91;2&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=C-terminal_telopeptide&amp;action=edit&amp;section=4\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><a href=\"/wiki/N-terminal_telopeptide\" title=\"N-terminal telopeptide\">N-terminal telopeptide</a>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=C-terminal_telopeptide&amp;action=edit&amp;section=5\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap\"><ol class=\"references\">\n<li id=\"cite_note-MarxCTX-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-MarxCTX_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-MarxCTX_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-MarxCTX_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-MarxCTX_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-MarxCTX_1-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\">Marx, RE, et al. <u>Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment</u>, <i>J Oral Maxillofac Surg</i> 2007;65:2397-2410</span>\n</li>\n<li id=\"cite_note-ROSEN-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ROSEN_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ROSEN_2-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-ROSEN_2-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\">Rosen, HN, et al. <u>Serum CTX. A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy</u>. <i>Calcif Tissue Int</i> 2000;66:100</span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\">Marx, RE, et al. <u>Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic</u>. <i>J Oral Maxillofac Surg</i> 2003;61:1115</span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\">Ruggerio, SL, et al. <u>Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases</u>. <i>J Oral Maxillofac Surg</i> 2004;62:527</span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\">Ruggiero, SL. <u>Bisphosphonate-related Osteonecrosis of the Jaws</u>. <i>Compendium</i> 2008;29<b>(2)</b>:97\u2013105.</span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\">Ju, H, et al. <u>Comparison\nof analytical performance and biological variability of three bone resorption assays</u>. <i>Clin Chem</i> 1997;43:1570\u20131576</span>\n</li>\n</ol></div></div>\n\n<!-- \nNewPP limit report\nParsed by mw2289\nCached time: 20180915070217\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.064 seconds\nReal time usage: 0.080 seconds\nPreprocessor visited node count: 236/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 1179/2097152 bytes\nTemplate argument size: 556/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 3816/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.009/10.000 seconds\nLua memory usage: 696 KB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%   59.170      1 -total\n 36.28%   21.469      1 Template:Main\n 26.57%   15.721      1 Template:Reflist\n 26.15%   15.473      1 Template:Quotation\n  5.33%    3.156      1 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:31170355-0!canonical and timestamp 20180915070217 and revision id 768652572\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","*":"Chemical_pathology"},{"sortkey":"","*":"Dentistry"}],"links":[{"ns":0,"exists":"","*":"Acronym"},{"ns":0,"exists":"","*":"Biomarker (medicine)"},{"ns":0,"exists":"","*":"Bisphosphonate"},{"ns":0,"exists":"","*":"Bisphosphonate-associated osteonecrosis of the jaw"},{"ns":0,"exists":"","*":"Bone remodeling"},{"ns":0,"exists":"","*":"Bone resorption"},{"ns":0,"exists":"","*":"Drug holiday"},{"ns":0,"exists":"","*":"Kilogram"},{"ns":0,"exists":"","*":"Monoclonal antibody"},{"ns":0,"exists":"","*":"N-terminal telopeptide"},{"ns":0,"exists":"","*":"Osteoclast"},{"ns":0,"exists":"","*":"Osteoporosis"},{"ns":0,"exists":"","*":"Peptide"},{"ns":0,"exists":"","*":"Physiology"},{"ns":0,"exists":"","*":"Sensitivity and specificity"},{"ns":0,"exists":"","*":"Serum (blood)"},{"ns":0,"exists":"","*":"Surrogate endpoint"},{"ns":0,"exists":"","*":"Type-I collagen"}],"templates":[{"ns":10,"exists":"","*":"Template:Main"},{"ns":10,"exists":"","*":"Template:Quotation"},{"ns":10,"exists":"","*":"Template:Quote"},{"ns":10,"exists":"","*":"Template:Quote/styles.css"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Main"},{"ns":828,"exists":"","*":"Module:Hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote list"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":[],"externallinks":[],"sections":[{"toclevel":1,"level":"2","line":"Bisphosphonate-associated osteonecrosis of the jaw","number":"1","index":"1","fromtitle":"C-terminal_telopeptide","byteoffset":1219,"anchor":"Bisphosphonate-associated_osteonecrosis_of_the_jaw"},{"toclevel":1,"level":"2","line":"Risk determination","number":"2","index":"2","fromtitle":"C-terminal_telopeptide","byteoffset":2347,"anchor":"Risk_determination"},{"toclevel":1,"level":"2","line":"Use of the CTX biomarker","number":"3","index":"3","fromtitle":"C-terminal_telopeptide","byteoffset":2729,"anchor":"Use_of_the_CTX_biomarker"},{"toclevel":1,"level":"2","line":"See also","number":"4","index":"4","fromtitle":"C-terminal_telopeptide","byteoffset":5097,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"5","index":"5","fromtitle":"C-terminal_telopeptide","byteoffset":5138,"anchor":"References"}],"parsewarnings":[],"displaytitle":"C-terminal telopeptide","iwlinks":[{"prefix":"wikt","url":"https://en.wiktionary.org/wiki/telopeptide","*":"wikt:telopeptide"}],"properties":[{"name":"wikibase_item","*":"Q5005966"}]}}